X4 Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-79.2M | $-37.5M | $-101.2M | $-93.9M | $-88.7M | $-62.1M | $-52.8M | $-33.3M |
| Depreciation & Amortization | $1.3M | $796.0K | $419.0K | $513.0K | $499.0K | $351.0K | $103.0K | $103.0K |
| Depreciation | $500.0K | $300.0K | $400.0K | — | — | — | — | — |
| Amortization | — | $500.0K | $0 | $0 | — | — | — | — |
| Stock-Based Compensation | $4.3M | $8.2M | $8.7M | $5.2M | $6.2M | $5.4M | $2.1M | $759.0K |
| Net Cash from Operating Activities | $-85.6M | $-130.9M | $-96.5M | $-77.1M | $-70.9M | $-58.8M | $-48.1M | $-25.4M |
| Investing Activities | ||||||||
| Capital Expenditures | $0 | $326.0K | $60.0K | $103.0K | $615.0K | $1.4M | $174.0K | $0 |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $8.2M | $67.0M | $-14.9M | $-103.0K | $-615.0K | $-1.4M | $27.2M | $0 |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | $0 | $0 | $2.0M | $0 | $0 | — |
| Net Cash from Financing Activities | $238.6M | $20.3M | $88.5M | $117.2M | $74.2M | $12.4M | $140.7M | $6.9M |
| Net Change in Cash | $161.4M | $-43.8M | $-22.8M | $39.9M | $2.4M | $-47.4M | $119.6M | $-18.6M |
| Free Cash Flow | $-85.6M | $-131.2M | $-96.6M | $-77.2M | $-71.5M | $-60.2M | $-48.2M | $-25.4M |